During anti-EGFR therapy in CRC patients, CAF promotes tumor resistance to EGFR by secreting growth factors, such as FGF1, FGF2, HGF, TGF-β1 and TGF-β2 [302]. The gene discussed is TGFB2; the disease is colorectal carcinoma.